Lilly’s antibody for COVID-19 protection starts nursing home trialWhile the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug Share XLilly’s antibody for COVID-19 protection starts nursing home trialhttps://pharmaphorum.com/news/lillys-antibody-for-covid-19-protection-starts-nursing-home-trial/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
New digital health player HealthHero launches with Fernarzt buyThere’s a new kid on the block in digital health – called HealthHero – with aspirations to become Share XNew digital health player HealthHero launches with Fernarzt buyhttps://pharmaphorum.com/news/new-digital-health-player-healthhero-launches-with-fernarzt-buy/
Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in EuropeRoche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK Share XRoche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europehttps://pharmaphorum.com/news/roches-tumour-agnostic-therapy-approved-in-europe/
Regeneron pairs with BioNTech on melanoma immunotherapyRegeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech Share XRegeneron pairs with BioNTech on melanoma immunotherapyhttps://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/
US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccineThe US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 Share XUS pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccinehttps://pharmaphorum.com/news/us-pays-sanofi-gsk-100-million-doses-covid-19-vaccine/
NICE backs kidney cancer combination from Merck KGaA and PfizerNICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first Share XNICE backs kidney cancer combination from Merck KGaA and Pfizerhttps://pharmaphorum.com/news/nice-backs-kidney-cancer-combination-from-merck-kgaa-and-pfizer/
The Planning Shop names Rebecca Rehder as global presidentBrand consultancy The Planning Shop has appointed Rebecca Rehder as global president, leading the organisation across the UK Share XThe Planning Shop names Rebecca Rehder as global presidenthttps://pharmaphorum.com/news/planning-shop-rebecca-rehder-global-president/
Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisitionGilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – Share XGilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisitionhttps://pharmaphorum.com/news/gilead-blames-3-3-billio/
